DOR BIOPHARMA ANNOUNCES ADVANCES IN MUCOSAL VACCINES FOR BOTULINUM TOXIN

DOR BioPharma, Inc. announced today the first successful evaluation in animal tests of a nasal, bivalent combination of its botulinum toxin vaccine, BT-VACC, addressing two of the most prevalent serotypes of botulinum toxin, types A and B. DOR is designing BT-VACC to be administered by the mucosal route, which offers significant advantages to the end user in terms of increased safety, lack of pain from injections, and ability to induce protective antibodies in the lung and intestines.
Business Wire